This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

This study has been completed.
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC Identifier:
First received: August 8, 2005
Last updated: September 20, 2012
Last verified: September 2012

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Vatalanib may stop the growth of tumor cells by blocking blood flow to the tumor. Giving temozolomide and radiation therapy together with vatalanib may kill more tumor cells.

PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of vatalanib when given together with temozolomide and radiation therapy and to see how well they work in treating patients with newly diagnosed glioblastoma multiforme.

Condition Intervention Phase
Brain and Central Nervous System Tumors Drug: temozolomide Drug: vatalanib Procedure: adjuvant therapy Radiation: radiation therapy Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Study on Concomitant and Adjuvant Temozolomide and Radiotherapy With or Without PTK787/ZK222584 in Newly Diagnosed GBM

Resource links provided by NLM:

Further study details as provided by European Organisation for Research and Treatment of Cancer - EORTC:

Primary Outcome Measures:
  • Dose-limiting toxicity and maximum tolerated dose of vatalanib as determined by CTCAE v3.0 during phase I
  • Progression-free survival at 6 months during phase II

Secondary Outcome Measures:
  • Severe toxic events as assessed by CTCAE v3.0 at weeks 3 and 6 (concomitant treatment), weeks 2 and 4 after radiotherapy, before each course of adjuvant treatment, monthly during maintenance treatment, and every 3 months during follow-up in phase II
  • Overall survival at 1 year during phase II
  • Correlation of angiogenesis and hypoxia markers expression and O-6-methylguanine DNA methyltransferase (MGMT) methylation status with clinical outcome during phase II

Enrollment: 20
Study Start Date: June 2005
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years to 69 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed glioblastoma multiforme

    • Newly diagnosed disease
  • Deemed to be amenable to concurrent and adjuvant temozolomide treatment by the principal investigator



  • 18 to 69

Performance status

  • ECOG 0-1

Life expectancy

  • Not specified


  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3


  • Bilirubin < 1.5 times upper limit of normal (ULN)
  • Alkaline phosphatase < 2.5 times ULN
  • ALT and AST < 2.5 times ULN


  • Creatinine ≤ 1.7 mg/dL


  • Cardiac function clinically normal
  • 12-lead ECG normal
  • No ischemic heart disease within the past 6 months
  • No uncontrolled cardiac arrhythmia
  • No uncontrolled hypertension
  • No history of stroke
  • No history of congenital long QT syndrome
  • QTc interval ≤ 450 msec for males or ≤ 470 msec for females by 12-lead ECG


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other malignancy except adequately treated basal cell or squamous cell skin cancer or cone biopsied carcinoma in situ of the cervix
  • No active uncontrolled infection
  • No other unstable systemic disease
  • No psychological, familial, sociological, or geographical condition that would preclude study compliance or follow-up schedule


Biologic therapy

  • No prior anti-vascular endothelial growth factor therapy


  • No prior chemotherapy

Endocrine therapy

  • Concurrent corticosteroids allowed provided the patient is on stable or decreasing doses for ≥ 2 weeks before study entry


  • No prior radiotherapy


  • More than 8 days, but < 6 weeks, since prior surgery or biopsy


  • No prior randomization on this study
  • No concurrent warfarin, warfarin-derived drugs, or similar anticoagulants
  • No other concurrent anticancer therapy
  • No other concurrent investigational agents
  • No concurrent enzyme inducing antiepileptic drugs, including any of the following:

    • Carbamazepine
    • Fosphenytoin
    • Oxcarbazepine
    • Phenobarbital
    • Phenytoin
    • Primidone
  • No concurrent grapefruit or grapefruit juice
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00128700

U.Z. Gasthuisberg
Leuven, Belgium, B-3000
Klinikum der Universitaet Regensburg
Regensburg, Germany, D-93053
Azienda Ospedaliera di Padova
Padova, Italy, 35128
Daniel Den Hoed Cancer Center at Erasmus Medical Center
Rotterdam, Netherlands, 3075 EA
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland, CH-1011
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Study Chair: Alba A. Brandes, MD Azienda Ospedaliera di Padova
  More Information

Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC Identifier: NCT00128700     History of Changes
Other Study ID Numbers: EORTC-26041-22041
Study First Received: August 8, 2005
Last Updated: September 20, 2012

Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
adult glioblastoma
adult giant cell glioblastoma
adult gliosarcoma

Additional relevant MeSH terms:
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms by Site
Nervous System Diseases
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors processed this record on June 23, 2017